Jong-Wei Hsu

Jong-Wei Hsu possesses extensive experience in biomedical research and development, currently serving as a Study Director at Labcorp since October 2025, overseeing non-regulated antibody studies. Hsu's previous role as Chief Consultant at Daiken Biomedical involves providing professional services for dietary supplement product development. Notable past positions include Scientist in Preclinical Development at Eisai US, where responsibilities included managing in vivo pharmacology studies for antibody-drug conjugate projects, and Senior Scientist I at WuXi AppTec, focusing on in vivo pharmacology projects. Hsu's academic background includes a PhD and MS in Lab Medicine and Pathology from the University of Rochester, as well as MS and BS degrees in Animal Sciences from National Taiwan University and National Chung Hsing University, respectively. A diverse research trajectory encompasses collaborations in oncology and innovative model development to explore human diseases.